Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common arthritis drug stop hand joint damage?

NCT ID NCT07501507

Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether methotrexate, a drug used for other types of arthritis, can slow joint damage in people with painful hand osteoarthritis that hasn't gotten better with standard treatments. About 170 adults with erosive hand osteoarthritis will receive either methotrexate or a placebo for one year. The main goal is to see if the drug reduces worsening of joint damage on X-rays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 170 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Digital osteoarthritis (IPD and IPP) according to ACR criteria (with an X-ray of the hands taken less than 3 months ago, showing at least 3 joints with digital osteoarthritis KL\>=2) and symptomatic for more than three months Exclusion Criteria: * Having a bilirubin level \> 5 mg/dl (85.5 µmol/l) * Pregnant or breastfeeding women (a urine pregnancy test will be performed on women of childbearing age), * Injection of hyaluronic acid within the previous 6 months, * Injection of cortisone derivatives within the previous 3 months, * Presence of psoriasis, * Inflammatory rheumatism, * Microcrystalline arthropathy, * Joint prosthesis in one of the joints of the hand, * Planned placement of a joint prosthesis in the hand during the study period, * Major progressive disease (life-threatening cardiovascular disease, hematopoietic cancers including myeloma, cancers with risk of bone metastases), * Liver failure. * Severe renal failure (creatinine clearance less than 50 ml/min). * Positive hepatitis B serology. * Tuberculosis, hepatitis C, HIV positive, or other immunodeficiency syndromes. * Uncontrolled infections. * Use of corticosteroids. * Use of morphine derivatives, * Taking Bactrim, * Taking high doses of aspirin (greater than or equal to 500mg/day), * Contraindications to the use of methotrexate,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erosive hand osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, hand

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Erosive hand osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nice

    Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.